Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In March
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
醫療保健領域超賣次數最多的股票爲買入被低估的公司提供了機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
RSI 是一種動量指標，它比較股票在價格上漲的日子和價格下跌的日子的走勢。與股票的價格走勢相比，它可以讓交易者更好地了解股票在短期內的表現。根據Benzinga Pro的數據，當相對強弱指數低於30時，資產通常被視爲超賣。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是該行業主要超賣參與者的最新名單，RSI接近或低於30。
Pacific Biosciences of California, Inc. (NASDAQ:PACB)
加州太平洋生物科學有限公司（納斯達克股票代碼：PACB）
- On Feb. 15, Pacific Biosciences posted a narrower-than-expected quarterly loss. "Our team successfully executed its goals in 2023 and launched PacBio on a trajectory this company has never seen before," said Christian Henry, President and CEO of PacBio. "We continue to build solutions across the workflow, allowing our customers to further scale on HiFi, and we are encouraged to see how researchers are already making discoveries and shifting paradigms with the power and economics of Revio and the extraordinary accuracy of Onso." The company's stock fell around 27% over the past five days and has a 52-week low of $4.0050 .
- RSI Value: 28.98
- PACB Price Action: Shares of Pacific Biosciences of California fell 4% to close at $4.1750 on Wednesday.
- 2月15日，太平洋生物科學公佈的季度虧損低於預期。PacBio總裁兼首席執行官克里斯蒂安·亨利表示：“我們的團隊在2023年成功實現了目標，並以該公司從未見過的軌跡啓動了PacBio。”“我們將繼續在整個工作流程中構建解決方案，使我們的客戶能夠在HiFi上進一步擴大規模，看到研究人員如何利用Revio的力量和經濟性以及Onso的非凡精度做出發現並改變範式，我們感到鼓舞。”該公司的股票在過去五天中下跌了約27％，並且 52 周低點爲 4.0050 美元 。
- RSI 值：28.98
- PACB價格走勢：加州太平洋生物科學公司股價週三下跌4％，收於4.1750美元。
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD)
艾恩伍德製藥公司（納斯達克股票代碼：IRWD）
- On Feb. 29, Ironwood Pharmaceuticals released topline results from its pivotal Phase 3 STARS trial of once-weekly subcutaneous apraglutide in reducing parenteral support (PS) (drugs given by routes other than the digestive tract) dependency in adult patients with short bowel syndrome with intestinal failure (SBS-IF). The company's stock fell around 19% over the past five days. It has a 52-week low of $8.07.
- RSI Value: 21.99
- IRWD Price Action: Shares of Ironwood Pharmaceuticals fell 7.5% to close at $8.62 on Wednesday.
- 2月29日，Ironwood Pharmicals發佈了其關鍵的三期STARS試驗的主要結果，該試驗每週一次的皮下阿普拉魯肽可減少成年短腸綜合徵合併腸衰竭（SBS-IF）患者的腸外支持（PS）（通過消化道以外途徑給藥的藥物）依賴。該公司的股票在過去五天中下跌了約19％。它 創下 52 周低點 8.07 美元。
- RSI 值：21.99
- IRWD價格走勢：週三，艾恩伍德製藥股價下跌7.5％，收於8.62美元。
Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Integra 生命科學控股公司（納斯達克股票代碼：IART）
- On Feb. 28, Integra Lifesciences posted downbeat quarterly results. The company's stock fell around 8% over the past five days and has a 52-week low of $33.44.
- RSI Value: 28.88
- IART Price Action: Shares of Integra LifeSciences fell 1.2% to close at $36.11 on Wednesday.
- 2月28日，Integra Lifesciences公佈了悲觀的季度業績。該公司的股票在過去五天中下跌了約8％，爲期52周 最低價爲33.44美元。
- RSI 值：28.88
- IART價格走勢：週三，Integra LifeSciences的股價下跌1.2％，收於36.11美元。
Read More: Kroger, Broadcom And 3 Stocks To Watch Heading Into Thursday
閱讀更多： 克羅格、博通和三隻股票在週四值得關注